Seeking Alpha

The FDA approves GlaxoSmithKline's (GSK) raxibacumab injection to treat inhalational anthrax, a...

The FDA approves GlaxoSmithKline's (GSK) raxibacumab injection to treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores. Raxibacumab is the first monoclonal antibody approved under the FDA’s Animal Efficacy Rule, which allows findings from animal studies to support FDA approval when it is not feasible or ethical to conduct trials in humans. In this case, because inhalational anthrax is a rare and lethal disease, it is not possible to conduct adequate trials in humans.
Comments (2)
  • Tommy_Finger
    , contributor
    Comments (320) | Send Message
     
    Note to Big Pharma: It's easier for EVERYONE if you chose easier-to-pronounce names!!
    14 Dec 2012, 04:57 PM Reply Like
  • BeachChicken
    , contributor
    Comments (207) | Send Message
     
    I'll learn to pronounce it, if it pushes up GSK
    15 Dec 2012, 03:18 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|